PTPRB and diabetes mellitus: ANGPT1, ANGPT1 mimetics, modified ANGPT1, genetic overexpression of Angpt1, Veptp-knockout, and ANGPT2 inhibition have all demonstrated protective effects in preclinical models of kidney injury, including UUO, ischemia/reperfusion, and conditions induced by diabetes (including db/db, streptozotocin-induced, and Akita mice), cyclosporine, and sepsis (23, 25–27, 35–38).